This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

K-V Pharmaceutical Announces Planned Transition Of Trading Of Class A And Class B Common Shares To The OTC Markets

ST. LOUIS, Aug. 6, 2012 /PRNewswire/ -- K-V Pharmaceutical Company (NYSE: KVa / KVb) ("K-V" or "the Company") today announced that its Class A and Class B common shares may be traded in the over the counter (OTC) market following the Company's suspension from the New York Stock Exchange ("NYSE").  However, K-V cannot ensure that either class of stock will be, or will continue to be, traded.  Trading in the OTC market may result in significantly lower trading volumes and liquidity for investors seeking to buy or sell shares of K-V's common stock.

Earlier today, the Company received notice from the NYSE that trading in its Class A and Class B common shares would be suspended, pending delisting, following the Company's voluntary filing for protection under Chapter 11 of the U.S. Bankruptcy Code on August 4, 2012.  The Company will not be challenging the NYSE's delisting action.

Court documents, claims forms and other documents related to K-V's Chapter 11 can be found at http://dm.epiq11.com/KVD.  Additional information and frequently asked questions (FAQs) for shareholders can be found at http://kvph.com.

About K-V Pharmaceutical Company

K-V Pharmaceutical Company is a specialty branded pharmaceutical company with a primary focus in the area of women's healthcare. As such, we are committed to advancing the health of women across all the stages of their lives.

For further information about K-V Pharmaceutical Company, please visit the Company's corporate website at www.kvph.com.

Cautionary Note Regarding Forward-looking Statements

This release contains various forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995 (the "PSLRA") and which may be based on or include assumptions concerning our operations, future results and prospects. Such statements may be identified by the use of words like "plan," "expect," "aim," "believe," "project," "anticipate," "commit," "intend," "estimate," "will," "should," "could," "potential" and other expressions that indicate future events and trends.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
SYM TRADE IT LAST %CHG

Markets

DOW 17,841.98 -86.22 -0.48%
S&P 500 2,080.15 -9.31 -0.45%
NASDAQ 4,919.6440 -19.6830 -0.40%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs